



agence d'évaluation de la recherche
et de l'enseignement supérieur

Department for the evaluation of
research units

AERES report on unit:

Génomique Fonctionnelle des Tumeurs Solides

Under the supervision of
the following institutions
and research bodies:

Université Paris Descartes

Université Paris 7 - Denis Diderot

Université Paris 13 - Paris-Nord

Institut National de la Santé et de la Recherche
Médicale



January 2013



agence d'évaluation de la recherche
et de l'enseignement supérieur

Research Units Department

President of AERES

Didier Houssin

Research Units Department

Department Head

Pierre Glaudes



Grading

Once the visits for the 2012-2013 evaluation campaign had been completed, the chairpersons of the expert committees, who met per disciplinary group, proceeded to attribute a score to the research units in their group (and, when necessary, for these units' in-house teams).

This score (A+, A, B, C) concerned each of the six criteria defined by the AERES.

NN (not-scored) attached to a criteria indicate that this one was not applicable to the particular case of this research unit or this team.

Criterion 1 - C1 : Scientific outputs and quality ;

Criterion 2 - C2 : Academic reputation and appeal ;

Criterion 3 - C3 : Interactions with the social, economic and cultural environment ;

Criterion 4 - C4 : Organisation and life of the institution (or of the team) ;

Criterion 5 - C5 : Involvement in training through research ;

Criterion 6 - C6 : Strategy and five-year plan.

With respect to this score, the research unit concerned by this report and its in-house teams received the following grades:

- Grading table of the unit: **Génomique Fonctionnelle des Tumeurs Solides**

| C1 | C2 | C3 | C4 | C5 | C6 |
|----|----|----|----|----|----|
| A+ | A+ | A | NN | A | A |

- Grading table of the team: **Génomique fonctionnelle**

| C1 | C2 | C3 | C4 | C5 | C6 |
|----|----|----|----|----|----|
| A+ | A+ | A | A | A | A+ |

- Grading table of the team: **mRNA translation control in p53 and MHC class I pathways**

| C1 | C2 | C3 | C4 | C5 | C6 |
|----|----|----|----|----|----|
| A+ | A | NN | NN | A | A |



Evaluation report

| | |
|----------------------------------------|---------------------------------------------|
| Unit name: | Génomique Fonctionnelle des Tumeurs Solides |
| Unit acronym: | |
| Label requested: | UMR_S |
| Present no.: | UMR_S674 |
| Name of Director (2012-2013): | Ms Jessica ZUCMAN-ROSSI |
| Name of Project Leader (2014-2018): | Ms Jessica ZUCMAN-ROSSI |

Expert committee members

| | |
|----------|----------------------------------------------------------------------------|
| Chair: | Mr Charles THEILLET, Université de Montpellier |
| Experts: | Mr Andrea de GOTTARDI, University of Bern, Switzerland |
| | Mr Diether LAMBRECHTS, University of Leuven, Belgium |
| | Mr Laurent LE CAM, Université de Montpellier |
| | Mr Philippe MARTEAU, Université Paris Descartes (representative of CNU) |
| | Ms Marie-Paule ROTH, Université de Toulouse (representative of CSS INSERM) |

Scientific delegate representing the AERES:

Mr Daniel OLIVE

Representative(s) of the unit's supervising institutions and bodies:

Ms Laurence LOMME, INSERM

Mr Stefano MARULLO, Université Paris Descartes

Mr Jean-Paul RICHALET, Université Paris 13



1 • Introduction

History and geographical location of the unit

The unit was originally created in 2005 under the direction of Mr Marco GIOVINI. Mr Marco GIOVINI left for a position in Los Angeles and gave the direction over to Ms Jessica ZUCMAN-ROSSI (JZR). The Unit was renewed in 2009 under her direction and will remain as such in the project for 2014-2019.

The unit is located on the premises of the Institut de Génétique Moléculaire of the University Paris 7, in the same building as the CEPH (centre d'étude du polymorphisme humain), in close vicinity of the Institut Universitaire d'Hématologie. For the next 5 year period, the unit will be joined by a team coming from UMR_S940, which is located one floor above within IGM. At the same time two groups are leaving the unit to respectively join the Pitié-Salpêtrière and the HEGP (Hôpital Européen George Pompidou) to develop their work.

Hence the new project will be refocused on liver carcinogenesis (Hepatocellular Carcinoma [HCC] and adenoma), Mesothelioma and studies related to the roles of mRNA translation in the regulation of the p53 pathway and immune evasion.

Management team

The present unit is single team lab structured in 4 thematic projects. It is a rather small structure with a director assisted by a single administrative staff. No management structure is described.

AERES nomenclature

SVE1_LS1; SVE1_LS2; SVE1_LS7

Unit workforce

| Unit workforce | Number as at 30/06/2012 | Number as at 01/01/2014 | 2014-2018 Number of project producers |
|--------------------------------------------------------------------------------------------------------------------|-------------------------|-------------------------|---------------------------------------|
| N1: Permanent professors and similar positions | 5 | 8 | 8 |
| N2: Permanent researchers from Institutions and similar positions | 4 | 3 | 3 |
| N3: Other permanent staff (without research duties) | 6 | 6 | 6 |
| N4: Other professors (Emeritus Professor, on-contract Professor, etc.) | 1 | 1 | 1 |
| N5: Other researchers from Institutions (Emeritus Research Director, Postdoctoral students, visitors, etc.) | 8 | 10 | 6 |
| N6: Other contractual staff (without research duties) | | | |
| TOTAL N1 to N6 | 24 | 28 | 24 |
| Percentage of producers | 100 % | | |



| Unit workforce | Number as at 30/06/2012 | Number as at 01/01/2014 |
|--------------------------------------------------------------------|--------------------------------|--------------------------------|
| Doctoral students | 15 | |
| Theses defended | 9 | |
| Postdoctoral students having spent at least 12 months in the unit* | 10 | |
| Number of Research Supervisor Qualifications (HDR) taken | 1 | |
| Qualified research supervisors (with an HDR) or similar positions | 9 | 12 |



2 • Assessment of the unit

Strengths and opportunities

Two strong teams developing excellent science.

International recognition and strong ties abroad.

Strong ties of the team leader with the Sanger Centre.

The team leader has over the past 5 years managed to be a central actor in the hepatocellular cancer field, in somatic genetics and more recently in predisposition and risk factors governing progression from benign to malignant disease.

Exceptional ties with the clinics in the field of liver cancer. The prospect of the team in Jean Verdier Hospital in Bondy joining the lab is considered a great opportunity. However, it may also be a threat (see below).

Unique positioning on mesothelioma. Only few teams have this expertise and such a collection of samples from a devastating disease, whose incidence may be rising due to other micro and nano fiber pollutants besides asbestos.

Recognized expertise of the new PI joining the lab in the p53 and immune evasion fields.

Strong support by Inserm in terms of yearly funding (high) and technical staff.

Weaknesses and threats

The scientific environment was felt as lacking dynamism and the lab to be working on its own.

The management plan needs to be clarified.

Interactions between both groups could be tightened.

Association with the clinical team in Jean Verdier Hospital in Bondy is both an asset and a threat. Since they are fairly distant from the site, keeping active ties will require determined action in the long run. Moreover, the team in Bondy is diverse (radiology, pathology, hepatology) and very clinically oriented, while the basic research team is centered on genomics and genetic aspects.

Integration and interactions with the Jean Dausset Foundation and neighboring labs and core facilities might be developed.

Bioinformatics development is good but still not sufficient given the importance of bioinformatics in many projects of the unit.

Recommendations

Set up a management team.

Develop internal scientific life and interactions between both teams.

improve relation with the Jean Dausset Foundation to improve integration of the Unit on the site. Everyone would benefit from it.

Ties with the neighboring IUH should be formalized.

Implement a pro-active strategy to attract new groups.



3 • Detailed assessments

Assessment of scientific quality and outputs

The unit has clearly excellent scientific outputs, with 127 publications in peer reviewed journals published by the unit in its present constitution. This number goes up to 182 including publications by the newcoming group. In total both teams have published 33 papers in journals with IF exceeding 10 (Nature, Nature genet, Cancer Cell, Mol Cell, Blood, JAMA, PNAS...).

Assessment of the unit's academic reputation and appeal

The present reputation of the Unit is directly related to that of her director, whose work in the field of tumor genomics is well known and respected at both the national and international level. The addition of the new Team will further increase the Unit's reputation and scientific quality. Indeed, the new team leader has contributed high profile papers to the very active field of p53 regulation. He made original observations that have brought clear novelty.

Both teams have hosted (and are hosting) a number of doctoral and post-doctoral students from abroad. This clearly indicates their strong reputation and appeal.

Assessment of the unit's interaction with the social, economic and cultural environment

The unit has filed and licenced a patent with Integragen SA and has plans on developing collaborations with this company. Results on Hepato Cellular cancer and Adenoma molecular subtypes are expected to have a strong impact on patient management and care in the future. The foreseen integration in the Unit of the group at the Jean Verdier Hospital is expected to increase the social impact. However, attractiveness towards young PIs could and should be improved.

Assessment of the unit's organisation and life

The unit is presently a rather small structure which seems to run on an informal setting. No clear mention is made in the written report of regular lab meetings, however, the addition of a new research group and that of the team of clinical researchers at the Hospital Jean Verdier in Bondy should make it necessary to define a formal structure of governance and formalize regular staff meetings and annual retreats.

Assessment of the unit's involvement in training through research

The number of PhD students (4 PhD students; 87 months) in the last 5 years is very good, although some improvement is possible. Students are given appropriate conditions to successfully reach their objective in 3 to 4 years and are encouraged to find post-doctoral positions abroad (in Europe or the US). They are provided with adequate assistance and supervision from their tutors and often can obtain also assistance by other students in the same group or from another group. Teamwork is well integrated in the lab culture. Possibilities of presenting their work are given during formal labmeetings, and during national or international congresses or seminars. Students also underscored that they have the possibility of interacting with their mentors in a rapid and informal fashion when required. Authorship on papers is not a source of dispute.

Assessment of the five-year plan and strategy

The strategy of the unit is clearly defined and focused on cancer genomics for what concerns team 1 and regulation of mRNA translation for Team 2. However, whereas the scientific plans of the respective teams appear clearly, future interactions and synergies between both teams have not been developed and it is felt that the unit would clearly gain from some reflexion at this level. Some hints could be given on p53 response to Endoreticulum stress and oxidative stress and some of the mutated genes acting in this pathway identified in the exome screens in HCC.

Moreover, the second objective presented by Team 2 on sporadic cancer in dogs in a comparative oncology program at the European level needs further clarification. Asked to clarify this point, the team leader explained that he is part of a group that has filed a COST action proposal that was not selected this year but ranked in good position, encouraging the promoters to resubmit in the future. Hence, how this program on canine cancer will impact on future projects in the Unit is not clear.



4 • Team-by-team analysis

Team 1 : Génomique fonctionnelle

Name of team leader: Ms Jessica ZUCMAN-ROSSI

Workforce

| Team workforce | Number as at 30/06/2012 | Number as at 01/01/2014 | 2014-2018 Number of project producers |
|-----------------------------------------------------------------------------------------|-------------------------|-------------------------|---------------------------------------|
| N1: Permanent professors and similar positions | 4 | 7 | 7 |
| N2: Permanent EPST or EPIC researchers and similar positions | 2 | 2 | 2 |
| N3: Other permanent staff (without research duties) | | | |
| N4: Other professors (PREM, ECC, etc.) | 1 | 1 | 1 |
| N5: Other EPST or EPIC researchers (DREM, Postdoctoral students, visitors, etc.) | 7 | 6 | 6 |
| N6: Other contractual staff (without research duties) | | | |
| TOTAL N1 to N6 | 14 | 16 | 16 |

| Team workforce | Number as at 30/06/2012 | Number as at 01/01/2014 |
|-------------------------------------------------------------------|-------------------------|-------------------------|
| Doctoral students | 7 | |
| Theses defended | 4 | |
| Postdoctoral students having spent at least 12 months in the unit | 4 | |
| Number of Research Supervisor Qualifications (HDR) taken | 1 | |
| Qualified research supervisors (with an HDR) or similar positions | 7 | 10 |



• Detailed assessments

Assessment of scientific quality and outputs

- The unit has clearly excellent scientific outputs, with 127 publications in peer-reviewed journals published by the unit in its present constitution. Among this abundant production, the number of articles in high impact journals is of particular note (Nature 2009, Nature Genetics in 2012, J Exp Med, Hepatology as senior authors).

- The team has singled out three themes/projects that will be continued in the next term: (1) molecular profiling and functional genomics of HCC and hepatic adenoma, (2) genetic predisposition in HCC, (3) molecular profiling of mesothelioma.

(1) molecular profiling and functional genomics of HCC and hepatic adenoma is under the direct supervision of the Unit's director. It is the area of research where the unit has in the current setting made the most outstanding production and on which it built its reputation. Outstanding observations such as the characterization of IL6/ STAT3 activation in cellular models overexpressing the different gp130, STAT3 and GNAS mutants identified in hepatocellular carcinoma (Nature 2009, J Exp Med 2009) are noticeable. Along the same lines the recent NGS screen of HCC which led to the identification of important oncogenic targets (WNT/ β -catenin, IRF2, RSK2, ARID... Nature Genetics, 2012). Each of these projects is built on unique and innovative approaches beyond the state-of-the-art. Furthermore, the team is remarkable for its excellent translational research such as the identification of distinct molecular subtypes of HCC (Hepatology 2007). In each of these different studies, the Laboratory has published in high impact journals.

(2) genetic predisposition in HCC. This project benefits from the expertise in the Unit in the identification of novel therapeutic targets and detailed knowledge on molecular pathways involved in HCC development. The interdisciplinary network the investigators have set up must be emphasized. The focus of the project is directed to a better understanding of early events in hepatocarcinogenesis with the aim of identifying patients who are at particular high risk of HCC. The whole project is based on genome wide association and involve GWAS studies, functional study of identified SNPs (when relevant), validation of the SNPs showing association in cirrhotic patients. This is a highly relevant project led by recognized experts in the field. Incidence of HCC is expected to increase in the next years and only a few effective therapeutic approaches exist. The group has built a large interdisciplinary network in France and abroad.

(3) molecular profiling of mesothelioma is led by a young CR1 INSERM, who joined the group 3 years ago and is associated to a researcher who historically started the work and is well introduced in sub-specialty networks. Globally, this theme is underrepresented in Team n°1, compared to the HCC theme. The project is based on molecular profiling and genomic approaches classically used in Team n°1 (transcriptome and sequencing, genome wide methylation profiling and miRNA expression patterns). There is a clear wish to develop functional approaches, using mesothelioma cell cultures the group has developed, and tumor samples. It is of note, that tumor samples are rare (it is not a frequent disease luckily) but the group has the proper networks in the field. The group is also interested in translational approaches and foresees different strategies to screen chemical compounds that could potentially inhibit carcinogenesis in subgroups of mesothelioma tumors. The level of publication is not comparable to that of the group working on hepatocellular tumors but the group is smaller and all the work currently being performed has not yet been published. Notably, the two permanent researchers of the group have jointly signed (first and last coauthors) the two most recent publications in specialty journals (Arch Pathol Lab Med, Am J Pathol.).

Assessment of the academic reputation and appeal

- The Laboratory is renowned for its expertise in deciphering the molecular genetic basis of HCC.
- The numerous invited reviews, commentaries and opinion articles (Hepatology, J Hepatology, J Clin Oncol, Dig. Surg., Digestive and Liver Disease, etc) witness the high international academic reputation of this laboratory.
- The team leader sits on a number of scientific panels in France (INCa, LIGUE, Fondation de France, INSERM...) and abroad (AICR, WELBIO, Cancer Research UK, and many others) indicating the high level of recognition.
- The team is "équipe labellisée de la Ligue contre le Cancer, is a major partner in the ICGC program on HCC.
- The team leader is frequently invited to talk in plenary lectures in French (n=25) and international congresses (n=64) and has been awarded the Prix de la Recherche 2012 de l'INSERM. Those are clear signs of her high level of recognition in the academic world in France and at the international level.



Assessment of the interaction with the social, economic and cultural environment

- The written report makes mention of one patent that has been licensed to INTEGRAGEN SA in 2011 and one other patent in the process.
- Few collaborations with industry are mentioned.
- It must be acknowledged that improved diagnosis or molecular sub-classification of HCC will indirectly benefit HCC patients and their families and should have an important social impact (in the long-term).

Assessment of the unit's organisation and life

See assessment of the unit

Assessment of the team's involvement in training through research

See assessment of the unit

Assessment of the five-year plan and strategy

See identical assessment of the unit

Conclusion

● Strengths and opportunities

- The excellent publication record should facilitate securing funding, including from international agencies.
- International visibility, the proven track record and the fact that the proposed projects continue to build on existing biobanks and future prospects of collaboration with the group at the Jean Verdier Hospital in Bondy datasets are clear strengths of this group.
- The genetic predisposition project is considered a hot topic and an excellent opportunity to further increase the scientific impact of the findings that have been generated so far in the team. The group has the necessary know how to reach the objectives of the project and can rely on an established network of investigators and a large number of biological samples, patients and clinical data

A unique collection of primary cultures of 70 MPM (malignant pleural mesothelioma) samples established in the laboratory and characterized at the genetic and transcriptomic levels and good collaborations (HEGP, French Mesobank network) securing access to mesothelioma tumor collections

Strong support from the “Carte d’Identité des tumeurs” program from the LNCC

● Weaknesses and threats

- The Laboratory is planning to embark on a number of challenging projects, including some genomic, transcriptomic and methylomic large-scale projects. Although the group is well connected within the genomic community (numerous collaborations with leaders in the field, these heavy duty genomics projects involve a number of important challenges. These include the acquisition or privileged access to high-throughput sequencers (HiSeq or long-read sequencer) and a state-of-the-art computing infrastructure (data storage, computing power), as well as extensive bio-computing capacity

Only one definition of cirrhosis is given as a “control” group. However, there are several grades of cirrhosis according to measurements or criteria such as elastography, hepatic venous portal gradient, Child-Pugh score, and so on. These sub-categories of cirrhosis, together with the different etiologies should be considered.

- Also non-cirrhotic liver tissue should be included in these studies. Recent epidemiological studies indicate that in non-alcoholic steatohepatitis the risk of HCC may be significantly increased already before the development of cirrhosis.



The small size of the mesothelioma group and the variety of its projects may be a threat to their production and visibility in a highly competitive field. Hiring additional students and post-docs should be considered rapidly to strengthen this interesting line of research with important public health implications.

- Recommendations

At the moment, it seems that the Laboratory is capitalizing on outstanding collaborations, but they might consider investing also in staff members with the appropriate expertise to avoid being dependent on external collaborators.

- Future projects will need functional validation using molecular and cellular biology. This seems an important aspect of research to invest in and prioritize. So far, the combination of genetic (sequencing) and functional (molecular biology) expertise has been one of the unique strengths of the Laboratory.

- Mesothelioma

The current funding of this subgroup of team n°1 is not clear but it would be necessary to extend it by recruiting at least a post-doc and a PhD student.

The health risk that pose carbon nanotubes is very concerning if confirmed. The expertise of the group could probably be better used to address this important question.



Team 2 : mRNA translation control in p53 and MHC class I pathways

Name of team leader: Mr Robin FAHRAEUS

Workforce

| Team workforce | Number as at 30/06/2012 | Number as at 01/01/2014 | 2014-2018 Number of project producers |
|-----------------------------------------------------------------------------------------|-------------------------|-------------------------|---------------------------------------|
| N1: Permanent professors and similar positions | 1 | 1 | 1 |
| N2: Permanent EPST or EPIC researchers and similar positions | 2 | 1 | 1 |
| N3: Other permanent staff (without research duties) | 6 | 6 | 2 |
| N4: Other professors (PREM, ECC, etc.) | | | |
| N5: Other EPST or EPIC researchers (DREM, Postdoctoral students, visitors, etc.) | 1 | 4 | |
| N6: Other contractual staff (without research duties) | | | |
| TOTAL N1 to N6 | 10 | 12 | 4 |

| Team workforce | Number as at 30/06/2012 | Number as at 01/01/2014 |
|-------------------------------------------------------------------|-------------------------|-------------------------|
| Doctoral students | 8 | 3 |
| Theses defended | 5 | 1 |
| Postdoctoral students having spent at least 12 months in the unit | 6 | |
| Number of Research Supervisor Qualifications (HDR) taken | 0 | |
| Qualified research supervisors (with an HDR) or similar positions | 2 | 2 |



Detailed assessments

Assessment of scientific quality and outputs

Scientific production is of very high quality relative to the size of the research group with regular publications in journals with high impact factor (in average, one publication / year in journals with IF > 10). These publications are related to the 2 main basic research themes of the group that aims at understanding the importance of mRNA processing in regulation of the p53 tumor suppressor pathway and in immune evasion during viral infection. In addition to these major publications, members of the group have been participating in collaborative projects that led to several good to excellent publications. Basic research programs are well supported by important funding resources from INSERM and national agencies (ANR, INCa, ARC).

Regarding the 2 more translational research projects, the team leader announces that he has been coordinating a european network aiming at using the dog as a pre-clinical model for cancer research. This informal network has filed a COST action proposal that was not selected but got a reasonable rank, inciting them to renew the proposal. It is, however, difficult to evaluate its impact on the projects developed by this team. Scientific aims were not clearly defined and COST actions fund meetings where actors in a given field exchange information.

The team leader is also the scientific head of a medium-throughput screening facility dedicated to protein-protein interaction modulators that fosters collaborative projects with regular publications. No patent from this activity is yet available. This activity led the team leader to organize an EMBO workshop in 2012.

Assessment of the unit's academic reputation and appeal

The scientific production has provided the group with an excellent reputation, in particular in the p53 field which has been its most productive line of research. This scientific production led to the re-evaluation of some dogmas in the p53 field and has unraveled very interesting regulatory mechanisms that might play important roles during aging and carcinogenesis. Their findings regarding immune evasion during viral infection is also important and might lead to novel original therapeutic approaches in the future. The research group is well connected and is driving interesting collaborations, at both the national and international levels. The group is attractive for students and post-docs. Lack of information on their participation as invited or selected speakers in international meetings does not allow full evaluation of their academic influence.

Assessment of the unit's interaction with the social, economic and cultural environment

The team leader is the scientific director of the protein-protein interaction facility that aims at identifying small compounds with potential therapeutic applications. Again, little information was provided to the reviewers to assess the importance of the facility but it appears to be involved in collaborative projects with regular publications. The network on dog-oriented research is at its early stage so it is difficult to predict its added value.

Assessment of the unit's organisation and life

The team's life is centralized on its PI, who is the only senior researcher present on a day to day basis in the lab. The team leader expressed his deep satisfaction to join forces with Team n°1 and develop scientific interactions with this team.

Assessment of the unit's involvement in training through research

The team hosted numerous students at both the master and PhD levels. All PhD students have been very successful and ended their program with at least one publication as first authors in high impact factor journal. This is likely to reflect an excellent mentorship and scientific environment. One PhD student set up on her own initiative a meeting related to the p53 field that was restricted to PhD students. The group also hosted several junior and senior post-docs, including foreign post-docs. One senior post-doc will leave the RF lab soon to start his own "Avenir-ATIP" junior group.



Assessment of the five-year plan and strategy

Human resources dedicated to the 4 main research programs (2 basic and 2 translational) were not sufficiently described in the written report but this point was clarified during the visit. The p53-related projects are developed by sufficient number of students and post-docs. However, due to the departure of one senior post-doc that was key to projects related to immune evasion, it will be important to re-inforce human resources dedicated to this program to maintain competitiveness at the international level.

Conclusion

- Strengths and opportunities

The group develops excellent basic research programs with potential applications in oncology and immunity. Translational programs are of potential interest, with interesting perspectives in developing original therapeutic strategies, but yet not completely mature.

- Weaknesses and threats

The translational dog-orientated research program is both promising and challenging. However, it is not clear how the group will integrate this project with the ongoing basic research programs and with the rest of the unit research lines, including those that are currently developed by team 1. In particular questions arise on time constraints that may arise due to time consuming networking activities; that may contradict the need to maintain leadership on his fundamental aspects. Given the fact that the team leader is the only permanent staff scientist in his team, this may be a major threat.

- Recommendations

Hiring permanent staff scientists at the "chargé de Recherche" level could help re-inforce the leadership of the group within its scientific community, and help the group leader supervise a research group that will likely increase in size in the coming years. Improvements in the management strategy and organization of the unit should be discussed with the head of team 1 to provide a more attractive environment for young PIs.



5 • Conduct of the visit

Programme du Comité de visite
Unité Génomique fonctionnelle des tumeurs solides
17 01 2013, 27 rue Juliette Dodu, 75010 Paris
Directeur actuel : Ms Jessica ZUCMAN-ROSSI
Directeur proposé : Ms Jessica ZUCMAN-ROSSI

Délégué scientifique AERES: Daniel Olive

Comité Scientifique : Mr Charles THEILLET (Président) ; Experts Mr Diether LAMBRECHTS, Mr Andrea DE GOTTARDI, Mr Laurent LE CAM, Ms Marie-Paule ROTH (CSS2), Mr Philippe MARTEAU (CNU)

8h30 -9h00 Huis clos - Présentation de l'AERES au comité par le Délégué
9h00 -9h15 Devant l'unité, présentation du Comité de visite et Présentation de l'AERES par le Délégué
9:15-9:45 Ms Jessica ZUCMAN-ROSSI: *Présentation de l'unité, bilan et projet*
9:45-10:00 Discussion

AUDITION DES EQUIPES

10:00-10:10 Ms Jessica ZUCMAN-ROSSI: *Introduction of team 1 projects*
10:10-10:20 Ms Camilla PILATI: *Genomics of hepatocellular adenoma*
10:20-10:30 Ms Sandra REBOUSSOU: *Functional analysis of new therapeutic targets*
10:30-10:40 Mr Pierre NAHON: *Genetic predisposition to liver tumors*
10:40-11:15 Discussion
11:15-11:30 *Coffee break*
11:30-11:45 Mr Didier JEAN: *Mesothelioma projects*
11:45-12:00 *Discussion*
12:00-12:30 Mr Robin FAHRAEUS: *Team 2 projects*
12:30-13:00 Discussion

13:00-14 :00 *Déjeuner buffet*

SESSION RENCONTRE AVEC LE PERSONNEL PERMANENT ET NON PERMANENT

Le comité se répartit en trois sous-groupes

14:00 -14:30 Rencontre avec les ITA titulaires , CDD
Auditoire : membres du Comité, Délégué AERES, sans les Tutelles, ni la Direction

Rencontre avec les doctorants et post-doctorants et/ou CDD « chercheurs », Ingénieurs
Auditoire : membres du Comité, Délégué AERES, sans les Tutelles, ni la Direction

Rencontre avec les chercheurs et enseignants chercheurs titulaires.
Auditoire : membres du Comité, Délégué AERES, sans les Tutelles, ni la Direction, ni les responsables d'Equipes
14:30-14:45 *pause*
14:45-15:15 Rencontre avec les représentants de la Tutelle:
Auditoire : membres du Comité, Délégué AERES

15:15-15:30 Rencontre avec la direction de l'unité
Auditoire : membres du Comité, Délégué AERES

15:30-18:00 Réunion du comité à huis clos

Short visit of the laboratory occupied team1. No unexpected event.

Présence : membres du Comité, délégué AERES



6 • Statistics by field: SVE on 10/06/2013


Grades

| Critères | C1 Qualité scientifique et production | C2 Rayonnement et attractivité académiques | C3 Relations avec l'environnement social, économique et culturel | C4 Organisation et vie de l'entité | C5 Implication dans la formation par la recherche | C6 Stratégie et projet à cinq ans |
|----------|---------------------------------------|--------------------------------------------|------------------------------------------------------------------|------------------------------------|---------------------------------------------------|-----------------------------------|
| A+ | 67 | 62 | 52 | 73 | 65 | 60 |
| A | 57 | 67 | 71 | 45 | 65 | 63 |
| B | 12 | 7 | 4 | 7 | 6 | 14 |
| C | 0 | 0 | 0 | 3 | 0 | 1 |
| Non Noté | 3 | 3 | 12 | 11 | 3 | 1 |

Percentages

| Critères | C1 Qualité scientifique et production | C2 Rayonnement et attractivité académiques | C3 Relations avec l'environnement social, économique et culturel | C4 Organisation et vie de l'entité | C5 Implication dans la formation par la recherche | C6 Stratégie et projet à cinq ans |
|----------|---------------------------------------|--------------------------------------------|------------------------------------------------------------------|------------------------------------|---------------------------------------------------|-----------------------------------|
| A+ | 48% | 45% | 37% | 53% | 47% | 43% |
| A | 41% | 48% | 51% | 32% | 47% | 45% |
| B | 9% | 5% | 3% | 5% | 4% | 10% |
| C | 0% | 0% | 0% | 2% | 0% | 1% |
| Non Noté | 2% | 2% | 9% | 8% | 2% | 1% |

Histogram





7 • Supervising bodies' general comments

Vice Président du Conseil Scientifique

Paris le 29.03.2013

Vos ref : S2PUR140006307 –
Génomique fonctionnelle des
tumeurs solides - 0751721N

Monsieur Pierre GLAUDES
Directeur de la section des unités de recherche
Agence d'Évaluation de la Recherche et de
l'Enseignement Supérieur
20, rue Vivienne
75002 PARIS

Monsieur le Directeur

Je vous adresse mes remerciements pour la qualité du rapport d'évaluation fourni à l'issue de la visite du comité d'expertise concernant l'unité « Génomique fonctionnelle des tumeurs solides »

De même que le Directeur de l'unité, Jessica ZUCMAN-ROSSI, le Président et moi-même n'avons aucune remarque particulière à apporter.

Je vous prie d'agréer, Monsieur le Directeur, l'expression de ma considération distinguée.

Le Vice Président du Conseil Scientifique



Stefano Marullo, DM, DesSci